Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Morgane Thomsen, Jens J. Holst, Anna Molander, et al.
Psychopharmacology (2018) Vol. 236, Iss. 2, pp. 603-611
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Mette Kruse Klausen, Morgane Thomsen, Gitta Wörtwein, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 625-641
Open Access | Times Cited: 108
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Mette Kruse Klausen, Mathias E. Jensen, Marco Møller, et al.
JCI Insight (2022) Vol. 7, Iss. 19
Open Access | Times Cited: 91
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 81
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, et al.
EBioMedicine (2023) Vol. 93, pp. 104642-104642
Open Access | Times Cited: 55
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Fatima Quddos, Zachary Hubshman, Allison N. Tegge, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 53
Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
Candan Yasemin Eren, Arya Yigit, Ramazan Efe Dogruoz, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 14
Open Access | Times Cited: 72
The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Elisabet Jerlhag
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 36
Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 1061-1075
Open Access | Times Cited: 9
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Anders Fink‐Jensen, Gitta Wörtwein, Mette Kruse Klausen, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 9
GLP-1 programs the neurovascular landscape
Bandy Chen, Xiaofei Yu, Claudia Horvath-Diano, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2173-2189
Closed Access | Times Cited: 8
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
Jan Detka, Katarzyna Głombik
Pharmacological Reports (2021) Vol. 73, Iss. 4, pp. 1020-1032
Open Access | Times Cited: 47
Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study
Ida Kim Wium‐Andersen, Marie Kim Wium‐Andersen, Anders Fink‐Jensen, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 5, pp. 372-379
Open Access | Times Cited: 32
Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin
Maximilian Tufvesson‐Alm, Olesya T. Shevchouk, Elisabet Jerlhag
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 20
Effects of dulaglutide on alcohol consumption during smoking cessation
Leila Probst, Sophie Monnerat, D. Vogt, et al.
JCI Insight (2023) Vol. 8, Iss. 22
Open Access | Times Cited: 18
Novel medications for problematic alcohol use
Markus Heilig, Katie Witkiewitz, Lara A. Ray, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 11
Open Access | Times Cited: 6
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 6
Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
Annika Billefeld Bornebusch, Anders Fink‐Jensen, Gitta Wörtwein, et al.
eNeuro (2019) Vol. 6, Iss. 2, pp. ENEURO.0443-18.2019
Open Access | Times Cited: 47
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 5
A Complex Interplay between Nutrition and Alcohol use Disorder: Implications for Breaking the Vicious Cycle
Brooke White, Sunil Sirohi
Current Pharmaceutical Design (2024) Vol. 30, Iss. 23, pp. 1822-1837
Closed Access | Times Cited: 4
Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2025), pp. 101612-101612
Closed Access
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Mette Kruse Klausen, Gitte M. Knudsen, Tina Vilsbøll, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 3
Open Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder
Elisabet Jerlhag
Endocrinology (2025) Vol. 166, Iss. 4
Open Access
Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats
Daniel Vallöf, Aimilia Lydia Kalafateli, Elisabet Jerlhag
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 38
Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food
Kayla J. Colvin, Henry S. Killen, Maxwell J. Kanter, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9710-9710
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top